| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA812: Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | pralsetinib (Gavreto®) |
| Formulation | 100 mg hard capsules |
| Reference number | 4667 |
| Indication | For treating RET-positive advanced non-small-cell lung cancer after platinum-based chemotherapy |
| Company | Blueprint Medicines |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 08/10/2021 |
| NICE guidance | TA812: Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer |